We initiate coverage on GoHealth, Inc. (NASDAQ: NASDAQ: GOCO ) with a Strong Buy and $20 PT. GoHealth is a leading digital Medicare & health insurance brokerage marketplace utilizing AI-based plan optimization and consumer activation in the U.S. Our Strong Buy rating isMoretus Research delivers state-of-the-art, buy-side quality equity research for serious investors seeking clarity, conviction, and alpha. Focused on U.S. public markets, Moretus applies a structured, repeatable framework to identify companie ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of GoHealth, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Investigation and Class Action - Shareholders who purchased GoHealth securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to GoHealth [2]. Group 2: Allegations and Stock Impact - The U.S. Department of Justice announced charges against GoHealth, alleging that from 2016 to 2021, the company was involved in illegal kickbacks totaling hundreds of millions of dollars to brokers for enrollments in Medicare Advantage plans [3]. - Following the announcement of these charges, GoHealth's stock price dropped by 10.3% on May 1, 2025, and an additional 6.7% on May 2, 2025 [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered over $438 million for investors in 2019 alone [4].

WASHINGTON, May 20, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC is investigating GoHealth, Inc. (NASDAQ: GOCO) and certain of its officers and/or directors for potential securities fraud or other securities violations following a complaint recently filed by the Department of Justice alleging unlawful business practices involving a Medicare Advantage kickback scheme. If you are an investor in GoHealth, Inc. and purchased shares of GoHealth between 2016 and May 1, 2025, please consider contact ...

Financial Performance - Net revenues for Q1 2025 were $220,972,000, a 19% increase from $185,600,000 in Q1 2024[26] - Operating expenses totaled $214,303,000 in Q1 2025, up from $189,632,000 in Q1 2024, reflecting an increase of 13%[26] - The company reported an income from operations of $6,669,000 in Q1 2025, compared to a loss of $4,032,000 in Q1 2024[26] - Net loss attributable to GoHealth, Inc. was $4,408,000 in Q1 2025, an improvement from a net loss of $9,216,000 in Q1 2024[26] - The net income (loss) per share for Class A common stock was $(0.52) in Q1 2025, compared to $(1.04) in Q1 2024[26] - Comprehensive loss for Q1 2025 was $9,905,000, an improvement from a comprehensive loss of $21,351,000 in Q1 2024[30] - For the three months ended March 31, 2025, GoHealth reported a net loss of $9,786 thousand, compared to a net loss of $21,346 thousand for the same period in 2024, indicating a 54.2% improvement in net loss year-over-year[39] - Adjusted EBITDA for Q1 2025 was $42.060 million, a 56.4% increase from $26.894 million in Q1 2024, with an adjusted EBITDA margin of 19.0%[165] Assets and Liabilities - Total assets decreased to $1,382,067,000 as of March 31, 2025, down from $1,488,423,000 at the end of 2024[32] - Cash and cash equivalents decreased to $22,153,000 as of March 31, 2025, from $40,921,000 at the end of 2024[32] - Current liabilities decreased to $233,399,000 as of March 31, 2025, compared to $338,052,000 at the end of 2024[32] - The company had a total stockholders' equity of $397,086,000 as of March 31, 2025, down from $405,438,000 at the end of 2024[32] - As of March 31, 2025, the total long-term debt of the company is $446.4 million, a slight decrease from $447.9 million as of December 31, 2024[62] - The company reported a net cash used in operating activities of $12,405 thousand for Q1 2025, compared to net cash provided of $12,512 thousand in Q1 2024[39] - The company raised substantial doubt about its ability to continue as a going concern due to insufficient funding to meet obligations within the next twelve months[214] Revenue Sources - Medicare revenue increased to $219.404 million in Q1 2025, up 18.5% from $185.026 million in Q1 2024, driven by a significant rise in agency revenue[100] - Agency revenue, which includes commission revenue and partner marketing, reached $187.633 million in Q1 2025, a substantial increase of 89.4% compared to $99.124 million in Q1 2024[100] - The increase in net revenues was primarily driven by an $88.5 million rise in agency revenue, partially offset by a $54.1 million decrease in non-agency revenue[147] - The Company recognized $41.6 million in revenue from deferred revenue during Q1 2025, compared to $34.9 million in Q1 2024[110] Expenses - Share-based compensation increased to $2,803 thousand in Q1 2025 from $1,783 thousand in Q1 2024, reflecting a 57.0% increase[39] - Marketing and advertising expenses rose to $67.415 million in Q1 2025, a 27.7% increase from $52.775 million in Q1 2024, aimed at generating more qualified prospects[149] - General and administrative expenses increased by 33.9% to $22.656 million in Q1 2025, primarily due to costs associated with the e-TeleQuote acquisition[153] - Interest expense decreased to $15.954 million in Q1 2025 from $17.951 million in Q1 2024, reflecting a reduction in interest rates on the Term Loan Facility[155] Operational Changes - The company is currently in compliance with its financial covenants but faces substantial doubt about its ability to continue as a going concern due to potential liquidity constraints[50] - The company has developed mitigating plans to address potential liquidity constraints, including cost control measures and renegotiation of existing debt arrangements[50] - The company is actively looking to terminate or sublease certain office spaces and call centers as part of its cost savings initiatives[60] - The company completed the acquisition of e-TeleQuote on September 30, 2024, and excluded it from the internal control evaluation for the quarter ended March 31, 2025[207] Customer Engagement - Submissions increased to 303,026 in Q1 2025 from 216,148 in Q1 2024, indicating a significant growth in customer engagement[168] - For the three months ended March 31, 2025, the number of Submissions increased to 303,026, up 40.2% from 216,148 in the same period of 2024, primarily due to enhanced marketing efforts and increased agent headcount following the e-TeleQuote acquisition[170] Legal and Compliance - The company is contesting a derivative action related to alleged breaches of fiduciary duty, which may impact its financial condition[120] - The company is subject to various legal proceedings that could adversely affect its business and financial condition[213] - The company’s internal control over financial reporting was evaluated as effective as of March 31, 2025[205]

Stonegate Capital Partners Updates Coverage On GoHealth Inc. (GOCO) 2025 Q1May 14, 2025 4:36 PM EDT | Source: Reportable, Inc.Dallas, Texas--(Newsfile Corp. - May 14, 2025) - GoHealth Inc. (NASDAQ: GOCO): Stonegate Capital Partners updates their coverage on GoHealth Inc. (NASDAQ: GOCO). GoHealth, Inc. delivered a strong first quarter in 2025, highlighted by substantial revenue growth and operational efficiencies. Net revenues surged 19.1% year-over-year to $221.0M, driven by a 40.2% increase i ...

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GoHealth, Inc. (“GoHealth” or the “Company”) (NASDAQ: GOCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether GoHealth and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 1, 2025, th ...

GoHealth (GOCO) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.89 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -80.77%. A quarter ago, it was expected that this company would post earnings of $1.16 per share when it actually produced earnings of $2.41, delivering a surprise of 107.76%.Over the last four quarters, the company has surpassed ...

GoHealth (GOCO) Q1 2025 Earnings Call May 13, 2025 08:00 AM ET Speaker0 Good morning, and welcome to GoHealth's first quarter two thousand twenty five earnings conference call. My name is Tanya, and I'll be your operator for today's call. Currently, all participants are in a listen only mode. Following the prepared remarks, we will conduct a question and answer session. As a reminder, this conference is being recorded. I would now like to turn the call over to John Shave, Vice President of Investor Relation ...

First Quarter 2025 Results May 13, 2025 FORWARD-LOOKING STATEMENTS This earnings presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These forward-looking statements are made in reliance upon the safe harbor provision of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical ...

Financial Performance - First quarter 2025 net revenues reached $221.0 million, a 19.1% increase from $185.6 million in the prior year period[4] - The net loss for the first quarter 2025 was $9.8 million, reflecting a 54.2% improvement compared to a net loss of $21.3 million in the prior year period[4] - Adjusted EBITDA for the first quarter 2025 was $42.1 million, a 56.4% increase from $26.9 million in the prior year period[4] - Net revenues for Q1 2025 reached $220,972,000, a 19.1% increase from $185,600,000 in Q1 2024[19] - The company reported a net loss of $9,786,000 for Q1 2025, an improvement of 54.2% compared to a net loss of $21,346,000 in Q1 2024[19] - Adjusted EBITDA for Q1 2025 was $42,060,000, compared to $26,894,000 in Q1 2024, reflecting a significant increase[20] - The net income (loss) margin improved to (4.4)% in Q1 2025, compared to (11.5)% in Q1 2024[20] Operational Metrics - Submissions in the first quarter 2025 totaled 303,026, marking a 40.2% increase from 216,148 submissions in the prior year period[4] - The number of submissions increased by 40.2%, reaching 303,026 in Q1 2025, compared to 216,148 in Q1 2024[24] - Sales per submission decreased to $724 in Q1 2025, down 15.4% from $856 in Q1 2024[24] - Direct operating cost per submission improved to $522, an 18.4% decrease from $640 in the prior year period[4] - Direct operating cost per submission improved to $522 in Q1 2025, a reduction of 18.4% from $640 in Q1 2024[24] Revenue Sources - The company experienced a significant increase in commission revenue, which rose to $167,109,000 from $79,733,000 year-over-year[22] - Commissions receivable - current decreased to $207,443,000 as of March 31, 2025, down from $320,399,000 at the end of 2024[23] Strategic Initiatives - GoHealth launched GoHealth Protect, expanding its product offerings into guaranteed acceptance life insurance[4] - The company aims to enhance cash flow generation and reduce acquisition costs through the scaling of the new life insurance offering[3] - Investments in high-return initiatives are expected to drive continued momentum in future quarters[3] - The company is focused on refining its platform and technology to improve consumer experience and outcomes[3] - GoHealth's proprietary technology platform leverages machine-learning algorithms to match health plans to consumer needs[7]